Skip to Content
Morningstar
Get 14 Days Free

Smith & Nephew PLC ADR SNN

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Smith & Nephew Broadens Orthopedic Portfolio to Include Extremities; No Change to Our FVE

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

We expect Smith & Nephew’s integration of the extremities business from Integra LifeSciences to reinforce its narrow economic moat, but thus far, it adds little to our valuation as these products will account for roughly 2% of consolidated revenue. We interpret this acquisition through several lenses.

Read Full Analysis

Company Profile

Business Description

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and ENT technologies, and wound-care solutions. Slightly more than 40% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 27% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Contact
Hatters Lane, Building 5, Croxley Park
Watford, Hertfordshire, WD18 8YE, United Kingdom
T +44 1923477100
Sector Healthcare
Industry Medical Devices
Most Recent Earnings Dec 31, 2014
Fiscal Year End Dec 31, 2020
Stock Type —
Employees 18,581

Related

Stock Strategist Industry Reports
Will Robots Take Their Place in Orthopedics?
Robots are becoming more central to the orthopedic field, but widespread adoption still faces considerable hurdles.
Debbie Wang
Stock Strategist Industry Reports
Backlog Grows for Orthopedic Procedures
But the disruption caused by COVID-19 has little effect on the device industry’s moats.
Debbie Wang
Stock Strategist Industry Reports
Tides Turn for These Orthopedic Firms
Industry dynamics are shifting in the wake of Zimmer's Biomet acquisition.
Debbie Wang
Quarter-End Insights
Credit Outlook: Sector Updates and Top Bond Picks
Get our sector-by-sector take on the bond market, plus our five best bond ideas.
David Sekera
US Videos
Smith & Nephew: Innovation, Education Key to Emerging Market
Medical-device expansion in the BRIC countries will accelerate as price points are lowered and more doctors learn how to use orthopedics, says Smith & Nephew's Phil Cowdy.
Julie Utterback
Stock Strategist Industry Reports
Orthopedic Device Makers Take a Step Back
Competitive advantages appear to be weakening.
Julie Utterback
Quarter-End Insights
Our Outlook for Health-Care Stocks
With macro-conditions improving, the focus should return to fundamentals in health care.
Alex Morozov
Stock Strategist Industry Reports
Five Orthopedic Stocks for Your Watchlist
We see opportunities given the dire scenarios already baked into shares.
Julie Utterback
Premium Article
Been Waiting for a Pullback? Consider These Names
After the downturn on Thursday and Friday, these stocks are looking more attractively priced.
Jeremy Glaser
Investing Specialists
Ten Ultimate Stock-Pickers' Stocks to Consider in 2010
A walk through the securities highlighted during 2009 yields ten 5-star stocks.
The Morningstar Ultimate Stock-Pickers Team
Investing Specialists
What Stocks Might Jensen Be Buying?
Screening our stock universe using Jensen's guidelines produced some interesting results.
The Morningstar Ultimate Stock-Pickers Team
Stock Strategist Industry Reports
Orthopedic Device Firms on Sale
We see buying opportunities in this attractive niche.
Julie Utterback